Similarly, in obesity, GLP-1 RAs—particularly liraglutide and semaglutide—are generally prescribed in cases of more severe or refractory obesity, often following failure of lifestyle interventions or other pharmacotherapies [17]. This evidence concerns the gene GLP1R and obesity disorder.